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Abstract
The recent CORA (Controversies in Rheumatology and Autoimmunity) meeting held in 2013 represented a unique
opportunity for rheumatologists to address several topics. Among these, four topics include: (i) the role of
epigenetic changes in the pathogenesis of rheumatoid arthritis (RA), as shown by studies in monozygotic twins; (ii)
the cardiovascular and atherosclerotic risk in patients with RA treated with biologics; (iii) the use of new biomarkers
for the diagnosis and follow-up of RA and other autoimmune diseases, as represented by the new automatic
machines for anti-nuclear antibodies detection, or ultrasound imaging to follow RA progression; and (iv) the latest
guidelines on how to use and manage biologic therapies in RA and other autoimmune diseases, such as lupus. In
summary, we will herein present these topics of discussion and underline the conclusions obtained by rheumatologists
during the 2013 CORA Meeting.
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Introduction
In the last decade, autoimmune diseases have become a
hot topic of discussion because of their increasing preva-
lence worldwide. Thanks to the new findings in laboratory
and imaging techniques, it is now possible to achieve an
earlier diagnosis and to start follow-up and therapies as
soon as possible. However, despite significant improve-
ments in these aspects, we still face many limitations in
the management of autoimmune patients and in our pre-
vious contributions we have attempted to provide a pic-
ture of the current status of the hot topics that remain to
be solved in the field of rheumatology and autoimmunity
[1]. During the 2013 CORA (Controversies in Rheumato-
logy and Autoimmunity) congress held in Budapest, se-
veral such issues were directly addressed by authoritative
rheumatologists and are well illustrated by contributions
recently published in BMC Medicine. These include: (i)
the pathogenetic issues linked to epigenetics in rheuma-
toid arthritis (RA); (ii) the increased atherosclerotic and
cardiovascular risk in RA patients treated with biologic
therapy; (iii) the new laboratory and imaging biomarkers
in RA and other connective tissue diseases; and (iv) the
management of biologic therapies in RA and other auto-
immune diseases.
An epigenetic basis for RA
Numerous studies conducted in monozygotic (MZ) twins
have demonstrated that in the majority of pairs only one
of them will develop autoimmunity, despite the identical
genome [2,3], and this appears to be secondary to en-
vironmental factors acting on an individual suscepti-
bility through epigenetics. Epigenetic factors include DNA
methylation, histone deacetylation and expression of non-
coding small RNAs called microRNA [4] which cumula-
tively determine the cell-specific gene expression and,
when altered, may lead to the onset of autoimmune dis-
eases, as observed in systemic lupus erythematosus (SLE),
Sjögren syndrome and scleroderma [4-11]. This paradigm
applies also to RA, as discussed in the paper by Glant
et al. [12]. The authors provide a comprehensive review of
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the most controversial issues in epigenetics studies, such
as the importance of stating the specific cell type investi-
gated in epigenetic studies. In fact, the epigenetic signa-
ture varies widely in different cell types, as the authors
show when studying the DNA methylation status of RA
synovial fibroblasts and peripheral blood mononuclear
cells, similar to that observed elsewhere in effector cells
[11,13]. These mechanisms seem to act on the same
pathway able to control gene expression, the NFkB path-
way, and, thus, influence the inflammatory and immune
response.
The importance of studies on epigenetics relies on the
possibility to use the results for diagnostic and thera-
peutic purposes. In fact, several trials are ongoing for
the use of new therapies that alter the epigenetic sig-
nature in a specific disease, mainly in cancer, but no
epigenetics-based drug is currently approved for clinical
use [6].
The cardiovascular and cancer risks in rheumatology
Whether there is a higher risk of atherosclerosis and car-
diovascular events as well as cancer in patients with RA
and other autoimmune diseases is an issue of enormous
importance as the diagnosis of a rheumatological condi-
tion is made at increasingly young ages [14-16]. It is well
established that autoimmune diseases are characterized
by a chronic state of systemic inflammation [17,18], me-
diated also by microRNA [19-22] and by the production
of autoantibodies that can induce a higher risk of throm-
boembolism and atherosclerosis compared to the general
population [23,24], as observed in the antiphospholipid
syndrome [14,25]. Matsuura et al. describes the main
mechanisms that trigger inflammation in the atheroscler-
otic plaque, leading to its rupture and to the cardiovas-
cular event [26]. Among these factors, a key role is played
by pro-inflammatory cytokines (that is, interleukin-1 beta
(IL-1β)) and caspases that activate the NLRP3 inflamma-
some together with lysosomal damage and reactive oxygen
species. Of note, this unsuspected connection strengthens
the current view that autoimmunity and autoinflam-
matory diseases are indeed linked in their pathogenetic
mechanisms [27-29]. The prolonged inflammatory state
further induces the production of C-reactive protein
(CRP) that is capable of binding oxidized low density
lipoprotein (oxLDL) and this complex induces an alter-
ation of the arterial wall that accelerates atherosclerosis.
An antigenic component that plays a pathogenic role
in autoimmune diseases is β2GPI, well known as the tar-
get of anti- β2GPI antibodies in the anti-phospholipid
syndrome [17,30-33]. Also, this antigen can bind oxLDL
and lead to the perpetuation of the inflammatory state
in the vascular wall [17]. The two diseases considered by
Matsuura and colleagues as prototypes of chronic in-
flammation are RA and SLE which are associated with
an increased cardiovascular risk and because they have
high levels of anti-oxLDL and anti-oxLDL/β2GPI anti-
bodies. Also, anti-nuclear antibodies (ANA) are often
observed in autoimmune diseases [34,35] and a multiva-
riate analysis showed that ANA are inversely correlated
with carotid elasticity. From a cellular point of view, Th17
and Treg cells also play an important role in atherogen-
esis, which is protective and anti-atherogenic for Tregs
and is still unknown for Th17. In conclusion, the authors
describe all the inflammatory and autoimmune elements
that induce higher risk of atherosclerosis in autoimmune
diseases [26]. Damjanov et al. tackle the topic from a dif-
ferent point of view and address a key question which is
complementary to the former, that is, the effect of anti-
tumor necrosis factor alpha (TNFα) therapy on the car-
diovascular risk in RA patients [36]. The discussion of this
topic shows that biologic therapies reduce the cardio-
vascular risk in RA, as supported also by previous reports.
However, we remain unaware of the mechanisms by
which anti-TNFα therapies can influence the inflamma-
tory processes responsible for the altered vascular function
and lipid profile that is transiently modified [37]. An add-
itional element that Damjanov and colleagues consider
when describing the link of biologic therapy and car-
diovascular disease in autoimmunity is that these new
therapies also seem to increase the risk of cancer, mainly
represented by melanoma and non-melanoma skin cancer,
despite a possibly enhanced risk associated with auto-
immunity per se. In conclusion, biologic therapy reduces
the cardiovascular risk in RA but may be responsible for
increased risk of skin cancer. However, this risk should
not be considered sufficient to induce changes in clinical
practice or in treatment indication.
New frontiers in the use of biologic therapies
The use of biologic therapies for the treatment of RA
patients has completely changed the management and
follow-up of these patients in the last 15 years. Several
biologic drugs are now available, and they can be admin-
istered in different ways and with different timing, so
that rheumatologists can tailor the biologic therapy ac-
cording to what is better for each RA patient. However,
basic questions still remain open, as discussed by Van
Vollenhoven et al. [38] in this issue. The authors mainly
discuss the possibility that an early start of biologic ther-
apies can help in achieving remission of RA, and this
can later lead to better outcome and early interruption
of biologic therapies. Several trials are studying different
therapeutic approaches to be able to induce remission in
early RA patients who failed methotrexate monotherapy,
but results are not clear yet. Another hot topic concern-
ing biologic therapies is discussed in this issue by Gatto
et al. who discuss the possibility to use biologic therapies
off-label for patients with systemic lupus erythematosus
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(SLE) [39]. Several trials were started to test therapies
such as rituximab, epratuzumab, belimumab, abatacept
and anti-TNFα drugs in SLE patients, but only beli-
mumab has been approved and is currently available for
mild-to-moderate SLE patients. The reasons for the failure
of the other drugs are several, from the extreme hetero-
geneity of SLE disease manifestations to the differences of
the enrolled SLE population (that is, ethnic background,
past medications) and study design. So the next question
asked by Mocsai et al. is: what is the future of targeted
therapy in rheumatology? [40]. The authors attempt to an-
swer by considering the recent advances in the develop-
ment not only of biologics but also of small molecules for
rheumatic diseases, showing that these new therapies rep-
resent a big change in the management of rheumatic pa-
tients. Several trials are ongoing to test small-molecule
anti-rheumatic agents, to identify the better administra-
tion route and the characteristics of the target patients.
The authors expect wide development of new safe and
effective biologics in the future and also oral therapies
that could further improve the management of rheuma-
tic patients.
Diagnostic tools in rheumatology
Serum autoantibodies are the main laboratory biomarker
for the diagnosis of systemic autoimmune rheumatic dis-
eases and ANA identified by indirect immunofluorescence
have high sensitivity and specificity rates, albeit remaining
largely dependent on operator expertise. Meroni et al. de-
scribe the recent findings in automated ANA detection
and the strengths and limitations of this approach in clin-
ical practice [41], as discussed in a recent consensus study
and extensively during the CORA congress. In fact, tra-
ditional indirect immunofluorescence is time and labor
consuming, and is based on the recognition of specific
patterns by a skilled operator. To overcome these limita-
tions, new automated systems have been developed by
several companies to allow the recognition of ANA posi-
tive or negative samples that can be further characterized
by their specific pattern and titer [42,43]. The advantages
of these automated systems are obvious and include the
reduction of time and cost for indirect immunofluores-
cence (IIF), and the increased number of samples that can
be reliably tested, but problems have been also identified
[43]. For example, automated IIF for ANA detection fails
to describe accurately mixed patterns, cytoplasmic stain-
ing or rare patterns. These limits can be a serious problem
for the use of ANA in the diagnosis of autoimmune
diseases such as scleroderma [44], a disease character-
ized by the presence of rare and complex ANA pat-
terns at indirect immunofluorescence that cannot be
easily identified by current automated systems [35,45].
Meroni and colleagues state that despite several advan-
tages, automated ANA IIF assays need further study and
improvement before replacing standard IIF for ANA
detection [46].
Beside ANA, other autoantibodies are very important
for the diagnosis of rheumatic diseases, as in the case of
anti-citrullinated peptides antibodies (ACPA) in RA. In
the present issue, Senolt et al. [47] describe the recent
finding of new autoantibodies, the anti-carbamylated an-
tigens (anti-CarP) [48], peptidyl arginine deiminase type
4 (PAD4) and v raf murine sarcoma viral oncogene
homolog B1 (BRAF) [49,50]. Their role is to improve the
early diagnosis of RA, along with the classical and most
sensitive (albeit poorly specific) autoantibodies detected
in RA, such as the rheumatoid factor. The authors de-
scribe these serological biomarkers to underline their
predictive and prognostic value, and they also suggest a
role in therapy monitoring through the autoantibody
titer fluctuation, but this needs further investigation.
Ultrasound (US) imaging plays a growing role in RA
management together with the serological biomarkers
that were previously discussed. The same authors also il-
lustrate the main US features that help in the diagnosis
of RA [47]. In fact, US allows to identify fluid collection
in the joint, synovial hypertrophy, cartilage damage, bone
erosions, tendinopathy, enthesitis, and presence of a
Doppler signal if hyperemia due to inflammation is pre-
sent. The authors state that ultrasound can be currently
considered as a reliable biomarker of synovitis, and in fact
the EULAR/ACR 2010 classification criteria for RA in-
cluded US as a means of confirmation of clinical findings
of joint involvement.
Conclusions
It should now be clear from our discussion that the most
prominent issues in the management and understanding
of rheumatological conditions warrant an extensive dis-
cussion to gather sufficient agreement. As such, we are
convinced that opportunities such as the CORA meeting
that took place in 2013 and the one planned in Sorrento
on March 12-15, 2015 provide the ideal arena to address
the remaining questions on the table. With the growing
burden related to autoimmune diseases we are convinced,
for example, that a shared approach to the eligibility of pa-
tients to expensive treatments or a better understanding
of the true role of autoantibodies is to be encouraged
among experts worldwide.
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